Top 10 Undervalued Stocks This Week

Apogee Therapeutics continues to demonstrate exceptional 10x growth potential, with its recent positive 16-week Phase 2 APEX data for zumilokibart in atopic dermatitis reinforcing its best-in-class thesis in a multi-billion dollar market. The pivotal $1.3 billion strategic financing collaboration with Blackstone Life Sciences, described as non-dilutive for its royalty component, significantly de-risks its financial runway, providing ample capital for clinical development and commercialization efforts. While pre-revenue and reporting net losses (Q1 2026 EPS of -$1.06), its robust cash position and consistent execution on milestones foster high conviction for a substantial market re-rating as it progresses toward BLA submission. The CEO's insider selling (pre-Blackstone/data) is noted but does not outweigh the strong fundamental catalysts.

FICO continues to demonstrate exceptional operational strength, reinforced by its Q2 FY2026 earnings beat with 39% revenue growth and 69% GAAP EPS growth. The raised full-year guidance for FY2026, driven by strength in mortgage-related scores, FICO Platform growth, and the upcoming FICO Score 10T rollout, underscores expanding market leadership and pricing power. While a 10x return for a large-cap company like FICO is ambitious, its deep economic moat, consistent execution, and robust cash flow generation position it for substantial multi-bagger potential. The strong profitability trajectory and strategic capital allocation (aggressive buybacks, managed debt) further validate its high score. No material negative changes have occurred since the last analysis, maintaining the strong thesis.